Faves for this Web page

  • Sigalon - Jun 17 2008 | pd

    The Israel Parkinson Association welcomed with "excitement and joy" the results of a study showing Parkinson's drug Azilect (rasagiline), developed by Profs. Moussa Youdim and John Finberg of the Technion-Israel Institute of Technology, to be effective at slowing the progression of the chronic and fatal neurological disease, a first for any drug.

Add a Fave for this Web page

What happens when I press Publish?
Your Fave for this Web page gets shared with the Faves community. You can access it at any time by selecting "My Faves" from the menu above.
Why do you ask for my email address?
We use your email address to create an account, so you can easily find your Fave again at a later time.
Rate It

Separate each email address with a comma.
WE DO NOT SPAM | Please read our privacy policy.

Related Content from Around Faves

news

VIEW ALL

video

VIEW ALL